In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Ken Shreve and Ed Carson analyze Thursday's market action and discuss key stocks to watch on Stock Market Today.

Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.